Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents.

Autor: Garoon RB; Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA; Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA., Coffee RE; Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA., Jiang L; School of Medicine, Baylor College of Medicine, Houston, TX, USA., Weng CY; Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA., Carvounis PE; Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA.
Jazyk: angličtina
Zdroj: Journal of ophthalmology [J Ophthalmol] 2016; Vol. 2016, pp. 5282470. Date of Electronic Publication: 2016 Nov 17.
DOI: 10.1155/2016/5282470
Abstrakt: Aims. To compare visual and anatomic outcomes of adjunct intravitreous (IVT) triamcinolone acetonide to antivascular endothelial growth factor (VEGF) injections to IVT anti-VEGF injections alone for center-involving diabetic macular edema (DME) in treatment-naïve eyes. Methods. Retrospective study of treatment-naïve eyes with center-involving DME. The primary outcome was the change in best corrected visual acuity (BCVA) in eyes receiving only IVT anti-VEGF (group 1) and eyes receiving IVT anti-VEGF and adjunct IVT-TA (group 2). Results. Included were 192 eyes. The mean change in BCVA was +3.5 letters in group 1 compared to -3.5 letters in group 2 ( p = 0.048). Final macular thickness improved by -94  μ m in group 1 versus -68  μ m in group 2 ( p = 0.26). In group 1, 5/150 eyes compared to 9/42 eyes in group 2 (3.3% versus 21%, p = 0.0005) had a IOP >10 mmHg increase. Six of 126 phakic eyes in group 1 versus 12/33 phakic eyes in group 2 underwent cataract surgery (4.7% versus 36.3%, p = 0.00009). Conclusions. IVT-TA results in no additional benefit in eyes treated with anti-VEGF agents for DME.
Competing Interests: The authors declare that there is no conflict of interests regarding the publication of this paper.
Databáze: MEDLINE
Externí odkaz: